Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 153

1.

The blockade of immune checkpoints in cancer immunotherapy.

Pardoll DM.

Nat Rev Cancer. 2012 Mar 22;12(4):252-64. doi: 10.1038/nrc3239. Review.

2.

Immune checkpoint therapy for non-small-cell lung cancer: an update.

Xia B, Herbst RS.

Immunotherapy. 2016;8(3):279-98. doi: 10.2217/imt.15.123. Epub 2016 Feb 9. Review.

PMID:
26860624
3.

Combination cancer immunotherapy and new immunomodulatory targets.

Mahoney KM, Rennert PD, Freeman GJ.

Nat Rev Drug Discov. 2015 Aug;14(8):561-84. doi: 10.1038/nrd4591. Review.

PMID:
26228759
4.

Immune checkpoint combinations from mouse to man.

Ai M, Curran MA.

Cancer Immunol Immunother. 2015 Jul;64(7):885-92. doi: 10.1007/s00262-014-1650-8. Epub 2015 Jan 3. Review.

PMID:
25555570
5.

Immune checkpoint blockade: a common denominator approach to cancer therapy.

Topalian SL, Drake CG, Pardoll DM.

Cancer Cell. 2015 Apr 13;27(4):450-61. doi: 10.1016/j.ccell.2015.03.001. Epub 2015 Apr 6. Review.

6.

Immunotherapeutics for breast cancer.

Criscitiello C, Curigliano G.

Curr Opin Oncol. 2013 Nov;25(6):602-8. doi: 10.1097/CCO.0000000000000020. Review.

PMID:
24076578
7.

Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade.

Emens LA.

Expert Rev Anticancer Ther. 2012 Dec;12(12):1597-611. doi: 10.1586/era.12.147. Review.

8.

Inhibitory receptors as targets for cancer immunotherapy.

Turnis ME, Andrews LP, Vignali DA.

Eur J Immunol. 2015 Jul;45(7):1892-905. doi: 10.1002/eji.201344413. Review.

9.

Immune checkpoints and rheumatic diseases: what can cancer immunotherapy teach us?

van der Vlist M, Kuball J, Radstake TR, Meyaard L.

Nat Rev Rheumatol. 2016 Oct;12(10):593-604. doi: 10.1038/nrrheum.2016.131. Epub 2016 Aug 19. Review.

PMID:
27539666
10.

Immune Checkpoint inhibitors: An introduction to the next-generation cancer immunotherapy.

Lee L, Gupta M, Sahasranaman S.

J Clin Pharmacol. 2016 Feb;56(2):157-69. doi: 10.1002/jcph.591. Epub 2015 Sep 29. Review.

PMID:
26183909
11.

Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy.

Peggs KS, Quezada SA, Allison JP.

Immunol Rev. 2008 Aug;224:141-65. doi: 10.1111/j.1600-065X.2008.00649.x. Review.

PMID:
18759925
12.

Immuno-oncology: understanding the function and dysfunction of the immune system in cancer.

Finn OJ.

Ann Oncol. 2012 Sep;23 Suppl 8:viii6-9. doi: 10.1093/annonc/mds256. Review.

13.

Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies.

Philips GK, Atkins M.

Int Immunol. 2015 Jan;27(1):39-46. doi: 10.1093/intimm/dxu095. Epub 2014 Oct 16. Review.

PMID:
25323844
14.

Checkpoint blockade in cancer immunotherapy.

Korman AJ, Peggs KS, Allison JP.

Adv Immunol. 2006;90:297-339. Review.

15.

New checkpoints in cancer immunotherapy.

Ni L, Dong C.

Immunol Rev. 2017 Mar;276(1):52-65. doi: 10.1111/imr.12524. Review.

PMID:
28258699
16.

Checkpoint blockade for cancer therapy: revitalizing a suppressed immune system.

Pico de CoaƱa Y, Choudhury A, Kiessling R.

Trends Mol Med. 2015 Aug;21(8):482-91. doi: 10.1016/j.molmed.2015.05.005. Epub 2015 Jun 16. Review.

PMID:
26091825
17.

Immune checkpoint blockade immunotherapy to activate anti-tumour T-cell immunity.

Ramsay AG.

Br J Haematol. 2013 Aug;162(3):313-25. doi: 10.1111/bjh.12380. Epub 2013 May 21. Review.

PMID:
23691926
18.

[Immune-checkpoints: the new anti-cancer immunotherapies].

Ileana E, Champiat S, Soria JC.

Bull Cancer. 2013 Jun;100(6):601-10. doi: 10.1684/bdc.2013.1771. Review. French.

PMID:
23735730
19.

Immune Checkpoint Inhibitors for Cancer Therapy: Clinical Efficacy and Safety.

Azoury SC, Straughan DM, Shukla V.

Curr Cancer Drug Targets. 2015;15(6):452-62. Review.

PMID:
26282545
20.

Immune checkpoint modulation: rational design of combination strategies.

Zamarin D, Postow MA.

Pharmacol Ther. 2015 Jun;150:23-32. doi: 10.1016/j.pharmthera.2015.01.003. Epub 2015 Jan 10. Review.

PMID:
25583297

Supplemental Content

Support Center